12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

V81444: Phase Ib/II started

Vernalis began a double-blind, placebo-controlled, U.S. Phase Ib/II trial to evaluate 100 mg oral V81444 twice daily for 14 days in about 24 patients. Vernalis...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >